Upfront Immunotherapy for Metastatic Kidney Cancer
0 Visualizações
• 06/26/23
0
0
Embutir
administrator
Assinantes
Panelists Robert A. Figlin, MD, and Eric Jonasch, MD, provide insight on the implications of frontline trials for immunotherapy and cabozantinib use, and the rationale for combination trials for metastatic kidney cancer.
Mostre mais
Comentários do Facebook
SORT BY-
Melhores Comentários
-
Últimos Comentários